DNTH Dianthus Therapeutics, Inc. /DE/
Pharmaceutical Preparations · Nasdaq · SEC CIK 1690585 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY-67.3%
TTM net income YoY-91.1%
TTM EPS YoY-64.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-8,739.3%
Net margin-7,973.3%
FCF margin-6,349.4%
EBITDA margin-8,733.9%
Returns
ROE-38.4%
ROA-35.9%
ROIC (approx.)-36.4%
Asset turnover0.00x
Leverage & solvency
Liabilities / assets7.1%
Debt / equity0.00x
Current ratio13.32x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.80x
Accruals ratio-7.4%
Payout ratio—
Capex / revenue10.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $2.04M | $6.24M |
| R&D expense | $145.64M | $83.11M |
| SG&A expense | $34.33M | $24.99M |
| Operating income | -$177.93M | -$101.86M |
| Income tax | $0 | $0 |
| Net income | -$162.34M | -$84.97M |
| EBITDA | -$177.82M | -$101.77M |
| EPS (basic) | -4.20 | -2.55 |
| EPS (diluted) | -4.20 | -2.55 |
| Dividends declared per share | 0.00 | 0.00 |
| Weighted avg. shares (diluted) | 38.62M | 33.31M |
| Balance sheet | ||
| Cash & equivalents | $51.09M | $23.02M |
| Short-term investments | $353.21M | $252.45M |
| Receivables | $52,000 | $0 |
| Current assets | $409.44M | $280.90M |
| PP&E, net | $296,000 | $194,000 |
| Total assets | $530.92M | $374.01M |
| Current liabilities | $30.73M | $18.45M |
| Total liabilities | $37.52M | $21.53M |
| Shareholders' equity | $493.40M | $352.48M |
| Shares outstanding | 43.22M | 31.12M |
| Cash flow statement | ||
| Operating cash flow | -$129.06M | -$78.18M |
| Capital expenditure | $213,000 | $105,000 |
| Free cash flow | -$129.27M | -$78.28M |
| Investing cash flow | -$122.83M | -$286.81M |
| Financing cash flow | $280.12M | $255.62M |
| Depreciation & amortization | $111,000 | $96,000 |
| Stock-based compensation | $22.79M | $12.89M |
Free plan shows the latest 2 periods; Pro shows all 10 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.